Results for tag: "Trelegy Ellipta"

Trelegy Ellipta is a combination inhaler used to treat chronic obstructive pulmonary disease (COPD). It contains three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. The inhaler is designed to reduce inflammation in the airways, relax the muscles around the airways, and help keep the airways open. Trelegy Ellipta is a long-term maintenance treatment for COPD and is not intended for the relief of acute symptoms. The Trelegy Ellipta market is a subset of the larger respiratory drugs market. It is composed of a variety of products, including inhalers, nebulizers, and other treatments. These products are used to treat a range of respiratory conditions, including asthma, COPD, and cystic fibrosis. Some of the companies in the Trelegy Ellipta market include GlaxoSmithKline, AstraZeneca, Novartis, and Boehringer Ingelheim. These companies produce a variety of respiratory drugs, including Trelegy Ellipta, and are involved in research and development of new treatments. Show Less Read more